MannKind Corp (MNKD)

MannKind Corporation (NASDAQ: MNKD) has submitted a prospectus supplement to its automatic shelf registration statement, which includes a legal opinion from Cooley LLP validating the legality of its common stock issuance and sale. This filing was made with the SEC on August 21, 2026, and confirms that MannKind's common stock is traded on NASDAQ. The report also clarifies that MannKind does not qualify as an emerging growth company.

MannKind (MNKD) has filed a prospectus supplement and submitted a legal opinion from Cooley LLP regarding the issuance and sale of common stock under its existing automatic shelf registration on Form S-3. This action facilitates the company's ability to offer and sell common stock in the future. The legal opinion is attached as Exhibit 5.1 to a Current Report on Form 8-K.

MannKind Corporation (NASDAQ: MNKD) has registered for resale up to 12.85 million shares of common stock by existing selling stockholders. This includes 10.44 million issued shares and 2.41 million shares issuable upon the exercise of pre-funded warrants from a July 24, 2026 private placement, where common shares were sold at $3.89 and pre-funded warrants at $3.88 with a $0.01 exercise price. MannKind will not receive proceeds from this resale but will cover registration expenses, and the selling stockholders may use various methods for disposal.

MannKind Corporation recently reported rising second-quarter 2026 revenue to US$109.37 million, but also a shift from profit to a net loss of US$19.03 million. This return to losses, despite higher revenue, highlights pressure from the company's cost base. The article suggests that while the Technosphere platform and programs like Afrezza and INFLO 1 data for nintedanib DPI offer potential, increasing R&D and commercial costs remain a significant risk to future profitability.

HC Wainwright has lowered its Q3 2026 EPS estimate for MannKind to a loss of $0.10, and also reduced full-year estimates through 2030, citing weaker near-term profitability. Despite these revisions, analyst sentiment for MannKind remains largely positive with a consensus "Moderate Buy" rating and a $9.22 target price. The biopharmaceutical company's shares opened down 3.1%, and a director recently sold a significant number of shares.